IBNSINA PHARMA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.37 EGP | -7.06% |
|
-18.28% | -24.52% |
| Mar. 03 | Ibnsina Pharma Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 05 | Ibnsina Pharma(CASE:ISPH) added to EGX 30 Index | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,011 | 4,886 | 3,907 | 2,419 | 3,517 | 2,449 | - | - |
| Enterprise Value (EV) 1 | 8,932 | 5,829 | 5,724 | 5,781 | 3,517 | 6,098 | 6,011 | 5,715 |
| P/E ratio | - | 26.8 x | 15.7 x | 16.6 x | 18.5 x | 8.1 x | 6.31 x | 3.04 x |
| Yield | 0.71% | - | 2.47% | - | - | 1.6% | 3.18% | 6.17% |
| Capitalization / Revenue | 0.48 x | 0.26 x | 0.18 x | 0.11 x | 0.1 x | 0.07 x | 0.06 x | 0.05 x |
| EV / Revenue | 0.54 x | 0.31 x | 0.26 x | 0.26 x | 0.1 x | 0.17 x | 0.14 x | 0.11 x |
| EV / EBITDA | 11.9 x | 8.46 x | 6.79 x | 6.96 x | 2.46 x | 3.84 x | 3.28 x | 2.52 x |
| EV / FCF | -23.6 x | 16.3 x | -11.7 x | - | - | 9.76 x | 7.76 x | 6.42 x |
| FCF Yield | -4.24% | 6.14% | -8.52% | - | - | 10.2% | 12.9% | 15.6% |
| Price to Book | 7.1 x | 3.58 x | 3.13 x | 1.73 x | - | 1.47 x | 1.23 x | 0.96 x |
| Nbr of stocks (in thousands) | 1,119,994 | 1,119,994 | 1,119,994 | 1,120,000 | 1,120,000 | 1,008,000 | - | - |
| Reference price 2 | 7.153 | 4.363 | 3.489 | 2.160 | 3.140 | 2.430 | 2.430 | 2.430 |
| Announcement Date | 2/25/20 | 3/1/21 | 3/23/22 | 3/1/23 | 3/3/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 16,600 | 18,679 | 21,733 | 22,264 | 33,949 | 36,644 | 44,085 | 53,785 |
| EBITDA 1 | 750.4 | 689 | 842.8 | 830.5 | 1,432 | 1,587 | 1,832 | 2,272 |
| EBIT 1 | 653.3 | 530.2 | 709.5 | 652.4 | 1,312 | 1,426 | 1,555 | 1,717 |
| Operating Margin | 3.94% | 2.84% | 3.26% | 2.93% | 3.86% | 3.89% | 3.53% | 3.19% |
| Earnings before Tax (EBT) 1 | 420.9 | 292.2 | 425.3 | 175.3 | 268 | 361.3 | 443.3 | 600 |
| Net income 1 | 328.8 | 224.7 | 314.7 | 172.6 | 213.7 | 417 | 416.5 | 676 |
| Net margin | 1.98% | 1.2% | 1.45% | 0.78% | 0.63% | 1.14% | 0.94% | 1.26% |
| EPS 2 | - | 0.1629 | 0.2229 | 0.1300 | 0.1700 | 0.3000 | 0.3850 | 0.8000 |
| Free Cash Flow 1 | -378.3 | 357.9 | -488 | - | - | 624.8 | 774.2 | 890.3 |
| FCF margin | -2.28% | 1.92% | -2.25% | - | - | 1.7% | 1.76% | 1.66% |
| FCF Conversion (EBITDA) | - | 51.95% | - | - | - | 39.37% | 42.26% | 39.19% |
| FCF Conversion (Net income) | - | 159.33% | - | - | - | 149.82% | 185.89% | 131.71% |
| Dividend per Share 2 | 0.0510 | - | 0.0860 | - | - | 0.0390 | 0.0773 | 0.1500 |
| Announcement Date | 2/25/20 | 3/1/21 | 3/23/22 | 3/1/23 | 3/3/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|
| Net sales 1 | 5,629 | 4,914 | 5,550 |
| EBITDA | - | - | - |
| EBIT 1 | 257.9 | - | 161.8 |
| Operating Margin | 4.58% | - | 2.92% |
| Earnings before Tax (EBT) | - | - | - |
| Net income 1 | 137.2 | 29.64 | 30.99 |
| Net margin | 2.44% | 0.6% | 0.56% |
| EPS | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 11/14/21 | 8/14/22 | 11/15/22 |
1EGP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 921 | 943 | 1,817 | 3,362 | - | 3,649 | 3,562 | 3,265 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.227 x | 1.368 x | 2.156 x | 4.048 x | - | 2.299 x | 1.944 x | 1.437 x |
| Free Cash Flow 1 | -378 | 358 | -488 | - | - | 625 | 774 | 890 |
| ROE (net income / shareholders' equity) | 33.1% | 18.8% | 22.3% | 12.7% | - | 24.1% | 20.2% | 25.1% |
| ROA (Net income/ Total Assets) | 4.97% | 2.95% | 3.07% | 1.43% | - | 1.35% | 1.35% | 2% |
| Assets 1 | 6,615 | 7,626 | 10,267 | 12,074 | - | 30,889 | 30,852 | 33,800 |
| Book Value Per Share 2 | 1.010 | 1.220 | 1.120 | 1.250 | - | 1.650 | 1.970 | 2.520 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 353 | 230 | 148 | 798 | - | 286 | 327 | 366 |
| Capex / Sales | 2.13% | 1.23% | 0.68% | 3.59% | - | 0.78% | 0.74% | 0.68% |
| Announcement Date | 2/25/20 | 3/1/21 | 3/23/22 | 3/1/23 | 3/3/24 | - | - | - |
1EGP in Million2EGP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.43
EGP
Average target price
4.082
EGP
Spread / Average Target
+68.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.52% | 49.93M | |
| -33.59% | 15.3B | |
| -25.06% | 11.07B | |
| +9.74% | 6.13B | |
| -10.65% | 5.95B | |
| +0.88% | 4.79B | |
| +53.60% | 4.36B | |
| -10.49% | 3.69B | |
| -12.53% | 3.43B | |
| -6.77% | 3.05B |
- Stock Market
- Equities
- ISPH Stock
- Financials Ibnsina Pharma
